Literature DB >> 27670823

The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.

Harvey Pass1, Dorothy Giroux2, Catherine Kennedy3, Enrico Ruffini4, Ayten K Cangir5, David Rice6, Hisao Asamura7, David Waller8, John Edwards9, Walter Weder10, Hans Hoffmann11, Jan P van Meerbeeck12, Anna Nowak13, Valerie W Rusch14.   

Abstract

For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mesothelioma; Registry; Staging; TNM

Mesh:

Year:  2016        PMID: 27670823     DOI: 10.1016/j.jtho.2016.09.123

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  12 in total

Review 1.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

2.  Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Ryotaro Kamohara; Go Hatachi; Takeshi Nagayasu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-01-23       Impact factor: 1.520

3.  Malignant pleural mesothelioma-the impact of globalization on rare diseases.

Authors:  M Alireza Hoda; Till Ploenes; Clemens Aigner
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

4.  Staging in the era of international databases: documented improvements with remaining challenges.

Authors:  Robert B Cameron
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 5.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

6.  A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.

Authors:  Bill T V Duong; Licun Wu; Brenda J Green; Fatemeh Bavaghar-Zaeimi; Zongjie Wang; Mahmoud Labib; Yuxiao Zhou; Fernando J P Cantu; Thurgaa Jeganathan; Sandra Popescu; Jennifer Pantea; Marc de Perrot; Shana O Kelley
Journal:  EBioMedicine       Date:  2020-10-09       Impact factor: 8.143

Review 7.  Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.

Authors:  Alberto M Marchevsky; Andras Khoor; Ann E Walts; Andrew G Nicholson; Yu Zhi Zhang; Victor Roggli; John Carney; Anja C Roden; Henry D Tazelaar; Brandon T Larsen; Nolwenn LeStang; Lucian R Chirieac; Sonja Klebe; Ming-Sound Tsao; Marc De Perrot; Andrew Pierre; David M Hwang; Yin P Hung; Mari Mino-Kenudson; William Travis; Jennifer Sauter; Mary Beth Beasley; Françoise Galateau-Sallé
Journal:  Mod Pathol       Date:  2019-09-04       Impact factor: 7.842

8.  Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.

Authors:  Yasushi Shintani; Seiki Hasegawa; Teruhisa Takuwa; Keisuke Aoe; Katsuya Kato; Nobukazu Fujimoto; Yasuhiro Hida; Masahiro Morise; Yasumitsu Moriya; Takao Morohoshi; Meinoshin Okumura; Ichiro Yoshino
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.

Authors:  Andrew C Kidd; Michael McGettrick; Selina Tsim; Daniel L Halligan; Max Bylesjo; Kevin G Blyth
Journal:  BMJ Open Respir Res       Date:  2018-01-30

Review 10.  Clinical staging of malignant pleural mesothelioma: current perspectives.

Authors:  Maria Bonomi; Costantino De Filippis; Egesta Lopci; Letizia Gianoncelli; Giovanna Rizzardi; Eleonora Cerchiaro; Luigi Bortolotti; Alessandro Zanello; Giovanni Luca Ceresoli
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.